Philip P. Boudreau is President & VP at ABBOTT LABORATORIES (ABT). They have made 4 open-market trades across 1 company since 2020, most recently 2026-04-23.
CIK 0001805099
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $201K since 2026, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ABT | 2,200 | $231K |
Shares reported on the most recent Form 4, priced at the 2026-04-27 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ABT | BUY | 2026-04-23 | 2026-04-27 | $91.50 | $201K | -7.4% | -8.8% | +11.4% |
| ABT | SELL | 2025-08-08 | 2025-08-11 | $134.55 | $1.5M | +0.2% | -1.8% | -4.4% |
| ABT | SELL · 10b5-1 | 2023-06-16 | 2023-06-20 | $106.00 | $848K | +2.3% | +4.9% | -5.3% |
| ABT | SELL | 2021-10-25 | 2021-10-27 | $126.49 | $1.0M | -1.0% | -1.7% | -3.7% |
| ABT | SELL | 2020-03-13 | 2020-03-16 | $82.00 | $869K | +0.4% | +20.4% | +18.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.